Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kickback Suit Against Novartis Can Proceed, Judge Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Federal judge rules against Novartis’ motion to dismiss a whistleblower suit alleging violations of the anti-kickback statute and the False Claims Act, saying the government’s evidence is specific enough to proceed.

You may also be interested in...



AstraZeneca Settles Nexium Kickback Suit; Deals Prohibiting Authorized Generic Sales Alleged

AstraZeneca agreed to pay $7.9 million to resolve allegations it paid kickbacks to Medco Health Solutions for preferred formulary placement of Nexium.

Novo Probe By U.S. Expands To Insulin Manufacturing

Massachusetts U.S. Attorney’s office, which is also investigating firm’s marketing, now subpoenas Novo Nordisk for documents relating to potential issues at its plant in Kalundborg, Denmark.

Health Care Fraud Tipsters May Get Bigger Reward; Novartis Kickback Complaint Prompts CIA Review

HHS proposes to increase the potential reward for information leading to recovery of Medicare funds from $1,000 to $9.9 million; OIG is reviewing Novartis corporate integrity agreement compliance after government alleges company paid Myfortic kickbacks to pharmacies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS076527

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel